Background*

Dr. Flemming Ornskov, M.D., MBA, MPH, has been the Chief Executive Officer of Shire plc since April 30, 2013 and serves as its Managing Director. Dr. Ornskov served as Head of Human Genetic Therapies at Shire plc since March 31, 2013. Dr. Ornskov served as the Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer from 2010 to 2012. Prior to joining Bayer, Dr. Ornskov served as Global President, Pharmaceuticals and OTC ... at Bausch & Lomb, Inc., from 2008 to 2010. Dr. Ornskov also served as the Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc., from 2005 to 2006. In his pharmaceutical career he had roles of increasing responsibility at Merck & Co. Inc. and Novartis AG, following a distinguished period in hospital and academic medicine. Dr. Ornskov serves as the Non-Executive Chairman at Evotec AG. He has been a Director of Shire plc since January 2, 2013. Dr. Ornskov served as a Director at PCI Biotech Holding ASA from 2008 to January 2013. Dr. Ornskov received his MD from the University of Copenhagen, an MBA from INSEAD, and a Master of Public Health from the Harvard University.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.